The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-05-21
Target enrollment:
Participant gender:
Summary
This ia a single-arm, not-randomized, open-label phase II study. The purpose of this study is
to evaluate the safety and efficacy of KN046 (PD-L1 /CTLA-4 Bispecific antibody) combined
with Lenvatinib(TKI) for the treatment of advanced hepatocellular carcinoma.